- Home
- QUCY vs RDHL Comparison
QUCY vs RDHL Comparison
Compare QUCY & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | QUCY | RDHL |
|---|---|---|
| Founded | 2008 | 2009 |
| Country | Germany | Israel |
| Employees | 13 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9M | 5.4M |
| IPO Year | 2021 | 2012 |
Fundamental Metrics
Financial Performance| Metric | QUCY | RDHL |
|---|---|---|
| Price | $3.41 | $1.00 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 30.0M | 54.9K |
| Earning Date | 06-26-2026 | 04-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $74.34 | $381.91 |
| Revenue Next Year | $171.48 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.30 | $0.71 |
| 52 Week High | $3.97 | $3.31 |
Technical Indicators
Market Signals| Indicator | QUCY | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 93.25 | 54.18 |
| Support Level | $0.39 | $0.92 |
| Resistance Level | N/A | $1.07 |
| Average True Range (ATR) | 0.46 | 0.06 |
| MACD | 0.30 | -0.01 |
| Stochastic Oscillator | 67.06 | 37.28 |
Price Performance
Historical ComparisonAbout QUCY Mainz Biomed N.V. Ordinary Shares
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.